Summit Therapeutics Recognises C. difficile Awareness Month
04 nov. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Recognises C. difficile Awareness Month Company to Highlight Potential of Phase 3 Precision Antibiotic Ridinilazole...
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
07 oct. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes...
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
03 oct. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile...
Increased BARDA Award and Option Exercise
18 juin 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract...
Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
16 août 2018 07h00 HE
|
Summit Therapeutics plc
Brings Total Committed Funding Under BARDA Contract to $44 Million OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), a...
Summit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI
21 déc. 2017 02h00 HE
|
Summit Therapeutics plc
Summit to receive $2.5 million upfront paymentUp to $25 million in development, regulatory, pricing and initial sales milestonesSummit retains commercial rights to ridinilazole in rest of the world ...
Summit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic Ridinilazole
06 nov. 2017 09h29 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
09 oct. 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI
05 sept. 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
28 avr. 2017 18h30 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, April 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...